These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 14996627)

  • 21. Sequential treatment with exemestane and non-steroidal aromatase inhibitors in advanced breast cancer.
    Bertelli G; Garrone O; Merlano M; Occelli M; Bertolotti L; Castiglione F; Pepi F; Fusco O; Del Mastro L; Leonard RC
    Oncology; 2005; 69(6):471-7. PubMed ID: 16410685
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Emerging role of aromatase inhibitors in the adjuvant setting.
    Goss PE
    Am J Clin Oncol; 2003 Aug; 26(4):S27-33. PubMed ID: 12902874
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The evolving role of aromatase inhibitors in breast cancer.
    Mokbel K
    Int J Clin Oncol; 2002 Oct; 7(5):279-83. PubMed ID: 12402060
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Where do selective estrogen receptor modulators (SERMs) and aromatase inhibitors (AIs) now fit into breast cancer treatment algorithms?
    Howell A; Howell SJ; Clarke R; Anderson E
    J Steroid Biochem Mol Biol; 2001 Dec; 79(1-5):227-37. PubMed ID: 11850229
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Adjuvant use of aromatase inhibitors in postmenopausal women with breast cancer.
    Michaud LB
    Am J Health Syst Pharm; 2005 Feb; 62(3):266-73. PubMed ID: 15719584
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Update on the use of aromatase inhibitors in breast cancer.
    Brueggemeier RW
    Expert Opin Pharmacother; 2006 Oct; 7(14):1919-30. PubMed ID: 17020418
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Risks and benefits of aromatase inhibitors in postmenopausal breast cancer.
    Michaud LB; Buzdar AU
    Drug Saf; 1999 Oct; 21(4):297-309. PubMed ID: 10514021
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Are all aromatase inhibitors the same? A review of controlled clinical trials in breast cancer.
    Berry J
    Clin Ther; 2005 Nov; 27(11):1671-84. PubMed ID: 16368441
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Update on the current use of hormonals as therapy in advanced breast cancer.
    Vogel CL
    Anticancer Drugs; 2003 Apr; 14(4):265-73. PubMed ID: 12679730
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Aromatase inhibitors for treatment of postmenopausal patients with breast cancer.
    Tamaki Y; Miyoshi Y; Kim SJ; Tanji Y; Taguchi T; Noguchi S
    Expert Rev Anticancer Ther; 2003 Apr; 3(2):193-201. PubMed ID: 12722879
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Aromatase inhibitors for treatment of advanced breast cancer in postmenopausal women.
    Gibson LJ; Dawson C; Lawrence DH; Bliss JM
    Cochrane Database Syst Rev; 2007 Jan; (1):CD003370. PubMed ID: 17253488
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Aromatase inhibitors in the breast cancer clinic: focus on exemestane.
    Van Asten K; Neven P; Lintermans A; Wildiers H; Paridaens R
    Endocr Relat Cancer; 2014 Feb; 21(1):R31-49. PubMed ID: 24434719
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Aromatase inhibitors in breast cancer: an update.
    Lake DE; Hudis C
    Cancer Control; 2002; 9(6):490-8. PubMed ID: 12514567
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Antiaromatase agents: evolving role in adjuvant therapy.
    Jones SE
    Clin Breast Cancer; 2002 Apr; 3(1):33-42. PubMed ID: 12020394
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Aromatase inhibitors and inactivators for breast cancer therapy.
    Lønning PE
    Drugs Aging; 2002; 19(4):277-98. PubMed ID: 12038879
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The role of aromatase inhibitors in the adjuvant treatment of breast carcinoma: the M. D. Anderson Cancer Center evidence-based approach.
    Morandi P; Rouzier R; Altundag K; Buzdar AU; Theriault RL; Hortobagyi G
    Cancer; 2004 Oct; 101(7):1482-9. PubMed ID: 15378476
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Exemestane as first-line therapy in postmenopausal women with recurrent or metastatic breast cancer.
    Glück S
    Am J Clin Oncol; 2010 Jun; 33(3):314-9. PubMed ID: 19730353
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Exemestane: a novel aromatase inactivator for breast cancer.
    Jones SA; Jones SE
    Clin Breast Cancer; 2000 Oct; 1(3):211-6. PubMed ID: 11899645
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Aromatase inhibitors in adjuvant therapy for hormone receptor positive breast cancer: a systematic review.
    Eisen A; Trudeau M; Shelley W; Messersmith H; Pritchard KI
    Cancer Treat Rev; 2008 Apr; 34(2):157-74. PubMed ID: 18164821
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinical evaluation of the use of exemestane as further hormonal therapy after nonsteroidal aromatase inhibitors in postmenopausal metastatic breast cancer patients.
    Carlini P; Michelotti A; Ferretti G; Ricci S; Giannarelli D; Pellegrini M; Cresti N; Di Cosimo S; Bria E; Papaldo P; Fabi A; Ruggeri EM; Milella M; Alimonti A; Salesi N; Cognetti F
    Cancer Invest; 2007 Mar; 25(2):102-5. PubMed ID: 17453821
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.